CSL Ltd shares rebound modestly as brokers shift to cautious hold stance

CSL Ltd (ASX: CSL) shares rose about 0.5% to $122.29, marking a 15% gain over the past month and a 33% recovery since a 15‑year low in early June. Despite the rebound, the stock remains down roughly 29% year‑to‑date and is 51% lower than its price a year ago.

Broker sentiment has softened, with the majority now rating CSL a hold. Analysts’ average target price is $140.15, suggesting a potential 15% upside, while the median target of $131.48 implies an 8% gain. Some brokers remain bullish, forecasting up to $199.68 within 12 months. Morgans maintains a buy rating with a $147.59 target, citing the long‑term story, whereas Macquarie offers a neutral stance and a lower $114 target, pointing to uncertainties in CSL’s plasma and albumin businesses. Investors are awaiting the FY26 results for further clarity on the company’s financial turnaround.